All News

In a recent clinical trial, weekly semaglutide demonstrated promise as a nonsurgical, nonopioid intervention for reducing knee osteoarthritis pain.

Check out these important FDA updates from the month of October 2024.

Presenters at the National Community Pharmacists Association 2024 Annual Convention and Expo discussed workflow and the future of pharmacy as a patient destination.

Researchers conducted a systematic review of randomized trials to determine the efficacy of ketamine for patients with cancer.

Hurricane season brings extreme weather and health care disruptions, emphasizing the importance of medication preparedness for patients and pharmacists.

GoodRx’s new e-commerce service further expands access to Opill by allowing consumers to order the birth control directly to their homes without a prescription.

Lisa Faast, PharmD, Founder and CEO of Diversify Rx, discussed how technology is used to innovate within the pharmacy.

Women experiencing later menopause may face a heightened risk of asthma, underscoring the possible role of estrogen in the development of the condition.

Researchers addressed the gut-first hypothesis of Parkinson disease by identifying how mucosal damage impacts risk of development.

Johnson & Johnson announced results from its phase 3 GRAVITI trial exploring guselkumab’s results in subcutaneous (SC) induction and maintenance therapy for treating Crohn’s disease.

The addition of a 10 mg oxycodone hydrochloride tablet improves dosing flexibility and precision.

Researchers analyzed the lack of prevention and treatment options for managing drug-induced liver injury.

With nearly 7 million women living in a health care desert, pharmacists can provide crucial reproductive care services.

The NCPA 2024 Annual Convention and Expo runs through October 29, 2024, in Columbus, Ohio.

Before marketing your pharmacy’s immunizations services, check out these takeaways from NCPA.

Industry experts gathered to discuss pharmacy benefit managers, their current grasp on the drug supply chain, and how it all impacts independent pharmacies.

PBM reform legislation has progressed further in Congress than ever before.

A second immunization session focused on updates in meningococcal disease, HPV, and Mpox.

The digest was released at the NCPA 2024 Annual Convention and Expo.

Making the store’s front end a priority can increase revenue opportunities and boost pharmacy profit.

In case you missed it, this week we had stories about the FDA approval of Pfizer's RSV vaccine, vaccines and COVID-19 hospitalization in children, race-based disparities in multimodal analgesia, and more.

The Drug Enforcement Administration gives controlled substance licenses, and can just as easily take them away.

The first of a 2-part presentation focused on vaccines for COVID-19, flu, RSV, and pneumococcal disease.

The FDA has approved just the second treatment for uncomplicated urinary tract infections (UTIs) in the last 2 decades.

The cost effectiveness of biosimilar denosumab for postmenopausal osteoporosis varies significantly based on factors like adherence, subsequent therapies, and treatment duration.

As the H5 bird flu outbreak gradually impacts human health in the US, health care experts weighed in on possibilities of a future vaccine.

A series of posters presented at AMCP Nexus 2024 highlighted the evolving landscape of women's health, focusing on the use of medications for preterm birth prevention and the adoption of telehealth for prenatal consultations.

A recent study found the percentage of type 1 diabetes patients who were prescribed either GLP-1s or SGLT2 inhibitors increased from 0.7% to 8.3% between 2010 and 2023.